2026-04-13T02:48:47Zhttps://recercat.cat/oai/requestoai:recercat.cat:10230/720382025-12-06T15:56:39Zcom_2072_6col_2072_452952
RECERCAT
author
Pelkmans, Wiesje
author
Gispert López, Juan Domingo
2025-12-06T15:56:39Z
2025-12-06T15:56:39Z
2025-11-27T16:57:06Z2025-11-27T16:57:06Z20242025-11-27T16:57:06Z
http://hdl.handle.net/10230/72038
This scientific commentary refers to 'Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline' by Peretti et al. (https://doi.org/10.1093/brain/awae211).J.D.G. is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). J.D.G. has also received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant agreement 115952), EIT Digital (grant 2021), and from Ministerio de Ciencia y Universidades (grant agreement RTI2018-102261).
© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Alzheimer's disease
Glial fibrillary acidic protein
Brain
Pathology
Cognitive impairment
Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion